title: Editorial overview: cancer: from target discovery to targeted therapy: the risky business of target validation.
authors.affiliation: Translational Science, Oncology iMED, AstraZeneca, Alderley Park, Macclesfield, Cheshire, SK10 4TG, UK. Electronic address: francisco.cruzalegui@astrazeneca.com.
authors.forename: Francisco
authors.initials: F
authors.lastname: Cruzalegui
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D055808:Drug Discovery; D015972:Gene Expression Regulation, Neoplastic / Q000187:drug effects; D006801:Humans; D058990:Molecular Targeted Therapy; D009369:Neoplasms / Q000188:drug therapy* / Q000235:genetics / Q000378:metabolism / Q000473:pathology; D015398:Signal Transduction / Q000187:drug effects
chemical_list: D000970:Antineoplastic Agents